StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report issued on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The stock has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.
About Genocea Biosciences
Recommended Stories
- Five stocks we like better than Genocea Biosciences
- What is the Hang Seng index?
- Oil Prices Fall, Sector Pulls Back: Time to Buy this Stock?
- 3 Healthcare Dividend Stocks to Buy
- AI Boom Fuels Demand for Dominion Energy Stock
- How to buy stock: A step-by-step guide for beginners
- Cathie Wood Cuts Robinhood Holdings—Follow Her Lead or Stay Put?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.